Amphastar Pharmaceuticals AMPH Total Cost of Revenue
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amphastar Pharmaceuticals's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amphastar Pharmaceuticals's total cost of revenue?
- Amphastar Pharmaceuticals (AMPH) reported total cost of revenue of $100.85M in Q1 2026.
- How has Amphastar Pharmaceuticals's total cost of revenue changed year-over-year?
- Amphastar Pharmaceuticals's total cost of revenue increased by 18.3% year-over-year, from $85.28M to $100.85M.
- What is the long-term trend for Amphastar Pharmaceuticals's total cost of revenue?
- Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's total cost of revenue has grown at a 11.2% compound annual growth rate (CAGR), from $238.03M to $363.83M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.